Nitrogen Containing Hetero Ring Patents (Class 514/43)
  • Patent number: 11413342
    Abstract: The present application relates to antibodies that bind to small molecules such as cyclophosphamide, ifosfamide, and analogs thereof, and immunological assays for determining the presence and/or quantifying the amount of cyclophosphamide and/or ifosfamide in a sample. By way of example, such immunological assays can be used for environmental testing.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: August 16, 2022
    Assignee: Becton, Dickinson and Company
    Inventor: Brian P. Dwyer
  • Patent number: 11324764
    Abstract: Disclosed are methods and compositions for reducing the epigenetic age of organisms, especially that of adult humans, which provide for proliferating endogenous stem cells, removing aberrant epigenetic marks from chromosomes and mitochondrial DNA, and replacement of senescent cells.
    Type: Grant
    Filed: July 20, 2021
    Date of Patent: May 10, 2022
    Inventor: Louis Dischler
  • Patent number: 11299736
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
    Type: Grant
    Filed: October 14, 2020
    Date of Patent: April 12, 2022
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Patent number: 11298343
    Abstract: Methods for removing excess free ?-globin in erythroid cells and treating a thalassemia using an agent that activates Unc-51 Like autophagy activating Kinase (ULK) are described.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: April 12, 2022
    Assignee: ST. JUDE CHILDREN'S RESEARCH HOSPITAL
    Inventors: Mitchell J. Weiss, Mondira Kundu, Christophe Lechauve
  • Patent number: 11266599
    Abstract: An embodiment of the present invention provides for a dry powder pharmaceutical composition suitable for dispersion in an aerosol for inhaled administration to a patient with cancer, the composition comprising: a cytidine analogue including salts, solvates, hydrates, and esters thereof; and a pharmaceutically acceptable excipient together forming the dry powder pharmaceutical composition suitable for dispersion in the aerosol for administration via inhalation to the patient with cancer. Another embodiment provides for a method of making the composition and a further embodiment provides for a method a treating a patient in need thereof with the composition.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: March 8, 2022
    Assignee: Lovelace Biomedical Research Institute
    Inventors: Steven A. Belinsky, Philip J. Kuehl, Aaron Badenoch, Michael Burke, Devon Dubose
  • Patent number: 11260069
    Abstract: Compositions containing a combination of nicotinamide riboside and pterostilbene for treating neurodegenerative disorders, and methods of treating neurodegenerative disorders using these compositions and their equivalents are described. The neurodegenerative disorders that can be treated using these compositions or methods can include parkinson's disease, huntington's disease, alzheimer's disease, and the like. In an embodiment, the compositions containing a combination of nicotinamide riboside and pterostilbene can be prepared as oral formulations. In some embodiments, a dietary supplement comprises nicotinamide riboside and/or pterostilbene or equivalents.
    Type: Grant
    Filed: August 22, 2017
    Date of Patent: March 1, 2022
    Assignee: Elysium Health, Inc.
    Inventors: Eric Alexander Marcotulli, Daniel Antonio Alminana
  • Patent number: 11229664
    Abstract: Methods are presented for attenuating myelosuppressive side effects of treatment regimens, promoting thrombopoiesis and neutrophil production, and increasing efficacy of treatment regimens, by administering PF4-interacting heparinoids.
    Type: Grant
    Filed: August 15, 2019
    Date of Patent: January 25, 2022
    Assignee: CANTEX PHARMACEUTICALS, INC.
    Inventor: Stephen Marcus
  • Patent number: 11219632
    Abstract: An object of the present invention is to provide a material which can be safely ingested and which inhibits skin pigmentation. Therefore, the invention is a skin pigmentation inhibitor, containing a ?-nicotinamide mononucleotide or a pharmaceutically acceptable salt thereof; and a solvate thereof as an active ingredient; a health supplement which contains the skin pigmentation inhibitor and is ingested to inhibit skin pigmentation; and a method for inhibiting skin pigmentation, including ingesting the skin pigmentation inhibitor.
    Type: Grant
    Filed: February 8, 2018
    Date of Patent: January 11, 2022
    Assignee: ORIENTAL YEAST CO., LTD.
    Inventors: Tatsuya Shinzato, Tetsuro Enomoto, Hisataka Yasuda, Hideo Arai
  • Patent number: 11209421
    Abstract: The present invention provides an in vitro method for selecting a patient affected with a tumor for a treatment with an antitumor compound, wherein the method comprises a step of measuring the expression level of CDA (Cytidine Deaminase) in a cancer sample from said patient. When the CDA expression level of a cancer sample is lower than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 4, in particular aminoflavone. Alternatively, when the CDA expression level of a cancer sample is higher than the reference expression level, it is indicative that the patient is suitable for a treatment with an antitumor compound selected from the group consisting of the compounds of table 3, in particular dasatinib.
    Type: Grant
    Filed: March 31, 2017
    Date of Patent: December 28, 2021
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT CURIE
    Inventors: Mounira Amor-Gueret, Hamza Mameri
  • Patent number: 11197881
    Abstract: A reactivation composition for activating or re-activating expression of a silenced X chromosome gene in a cell includes a non-cytotoxic histone deacetylase (HDAC) inhibitor. The reactivation composition includes the non-cytotoxic HDAC inhibitor and may further include a DNA methylation inhibitor. A method of activating or re-activating expression of a silenced X chromosome gene in a cell includes administering a reactivation composition including a non-cytotoxic HDAC inhibitor. The method of activating or re-activating expression of a silenced X chromosome gene may further includes administering a reactivation composition that includes a non-cytotoxic HDAC inhibitor and an inhibitor of DNA methylation.
    Type: Grant
    Filed: October 27, 2017
    Date of Patent: December 14, 2021
    Assignee: California Institute of Technology
    Inventors: Mitchell Guttman, Chun-Kan Chen
  • Patent number: 11198699
    Abstract: Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein) and methods of synthesizing the same. Also provided herein are methods of treating diseases and/or conditions with a compound of Formula (I), or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: December 14, 2021
    Assignee: Aligos Therapeutics, Inc.
    Inventors: Koen Vandyck, Pierre Jean-Marie Bernard Raboisson, Jerome Deval, Leonid Beigelman, David McGowan, Yannick Debing
  • Patent number: 11192914
    Abstract: This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the nucleotide or nucleoside is defined by Formula I below,
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: December 7, 2021
    Assignee: Emory University
    Inventors: Gregory Bluemling, Abel De La Rosa, George Painter, Damien Kuiper, Alexander Kolykhalov
  • Patent number: 11155571
    Abstract: The present application relates to a salt of a pyranose-substituted heterocyclic compound, a preparation method therefor, and use thereof, and in particular, to an acid addition salt of a compound of formula (I) or a prodrug thereof, and further relates to D-glucuronate of a crystalline compound of formula (I) or a prodrug thereof. D-glucuronate of a crystalline compound of formula (II) has particular advantages in terms of crystallizability, subsequent purification, stability, formulation medicinal properties or quality control, and is most applicable for improving the formulation pharmaceutical properties, purity and quality control, as well as large-scale process development of such drugs.
    Type: Grant
    Filed: February 3, 2019
    Date of Patent: October 26, 2021
    Assignees: Yabao Pharmaceutical Group Co., Ltd., Suzhou Yabao Pharmaceutical R&D Co., Ltd.
    Inventors: Fei Zhang, Peng Wang, Lin Zhu, Lili Sun
  • Patent number: 11147784
    Abstract: Methods and compositions for treating cancer and other disorders associated with undesired cellular proliferation are provided comprising administering to a subject in need thereof an amino acid mixture, wherein the amino acid mixture comprises glycine, optionally comprising at least a 2:1 molar ratio of glycine to serine.
    Type: Grant
    Filed: March 12, 2019
    Date of Patent: October 19, 2021
    Assignees: THE TRUSTEES OF PRINCETON UNIVERSITY, MEMORIAL SLOAN-KETTERING CANCER CENTER
    Inventors: Joshua D. Rabinowitz, Craig B. Thompson, Jiangbin Ye, Jing Fan, Jurre Kamphorst
  • Patent number: 11116777
    Abstract: Disclosed herein are conditioning regimens and methods for inducing MHC- or HLA-mismatched mixed chimerism by conditioning a recipient with radiation-free, low-doses of cyclophosphamide (CY), pentostatin (PT), and anti-thymocyte globulin (ATG) prior to transplantation of donor bone marrow cells. In certain embodiments, the donor bone marrow cells may be CD4+ T-depleted bone marrow cells. The conditioning regimens and methods may also include administering one or more populations of conditioning donor cells selected from donor CD4+ T-depleted spleen cells, donor CD8+ T cells, and donor G-CSF-mobilized peripheral blood mononuclear cells. The conditioning regimen is clinically acceptable and can be used for treating hereditary hematological diseases and autoimmune diseases, as well as for promoting organ transplantation immune tolerance.
    Type: Grant
    Filed: November 10, 2016
    Date of Patent: September 14, 2021
    Assignee: CITY OF HOPE
    Inventor: Defu Zeng
  • Patent number: 11071747
    Abstract: Certain embodiments of the invention provide a method for breast enhancement in a female mammal (e.g., a human) in need thereof, comprising administering an effective amount of a nicotinamide adenine dinucleotide (NAD) precursor to the mammal.
    Type: Grant
    Filed: November 29, 2017
    Date of Patent: July 27, 2021
    Assignee: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Charles M. Brenner, Po Hien Ear, Ankita Chadda, Amy Sindler, Marie E. Migaud
  • Patent number: 11059848
    Abstract: The present invention relates to artemisinic acid glycoconjugate compounds. More particularly, the present invention relates to a glycoconjugate compound of formula (I) and a process for the preparation of artemisinic acid glycoconjugate compound of formula (I) by using 1,3-dipolar cycloaddition chemistry starting from artemisinic acid.
    Type: Grant
    Filed: January 3, 2019
    Date of Patent: July 13, 2021
    Inventors: Asish Kumar Bhattacharya, Tharun Kumar Kotammagari, Manas Kumar Santra
  • Patent number: 11052100
    Abstract: A nicotinamide riboside composition and preparation method thereof, the icotinamide riboside composition comprises nicotinamide riboside and/or a salt thereof and konjac glucomannan or rebaudioside A. The nicotinamide riboside composition provided by the present invention, used to increase the concentration of NAD in cells, thereby preventing and improving various unhealthy conditions caused by NAD deficiency. is stable in property and easy to store and transport.
    Type: Grant
    Filed: August 17, 2018
    Date of Patent: July 6, 2021
    Assignees: BONTAC BIO-ENGINEERING (SHENZHEN) CO., LTD, BONTAC INVITROLIFE BIO-TECHNOLOGY (SHENZHEN) CO., LTD, JIANGXI BONZYMES BIOTECHNOLOGY CO., LTD.
    Inventors: Rongzhao Fu, Zhenwei Li, Xinglin Guo
  • Patent number: 11033567
    Abstract: This invention is directed to compositions for promoting wound healing and regeneration and methods of use thereof. In one aspect, methods for promoting wound healing in a subject are provided, the methods comprising: administering a therapeutically effective amount of a DNA methyl transferase inhibitors (DNMT) to the subject. In another aspect, methods for reducing scarring during healing of a skin wound are provided, the methods comprising: administering a therapeutically effective amount of a DNMT inhibitor.
    Type: Grant
    Filed: July 21, 2015
    Date of Patent: June 15, 2021
    Assignee: THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA
    Inventors: George Cotsarelis, Jen-Chih Hsieh, Ying Zheng
  • Patent number: 11029317
    Abstract: Provided herein are methods, compositions, and kits for diagnosing allograft rejection of organ transplants by identifying the presence of anti-endothelial cell antibodies. Such methods and compositions are independent of external confounders such as recipient age, transplant center, assay, cause of end-stage disease, co-morbidities, immunosuppression usage, and the like.
    Type: Grant
    Filed: September 18, 2015
    Date of Patent: June 8, 2021
    Assignees: The Johns Hopkins University, Immucor GTI Diagnostics, Inc.
    Inventors: Minnie M. Sarwal, Tara Sigdel, Annette M. Jackson
  • Patent number: 11013733
    Abstract: Patients diagnosed with a cancer harboring an IDH-1 mutation can be treated by the administration of a therapeutically effective amount of a pharmaceutical composition comprising Compound 1, a selective inhibitor of 2-HG production from mIDH-1 enzymes including the R132 mutations R132C, R132H, R132L, R132G, and R132S.
    Type: Grant
    Filed: June 4, 2019
    Date of Patent: May 25, 2021
    Assignee: FORMA Therapeutics, Inc.
    Inventors: Susan Ashwell, Blythe Thomson, Patrick F. Kelly, Alan Collis, Jeff Davis, Duncan Walker, Wei Lu
  • Patent number: 10874702
    Abstract: The present invention provides a topical composition comprising extract from Coriolus versicolor for use for preventing and/or treating by vaginal or cervical administration of a vaginal or cervical disorder which is caused by an infectious agent, in particular, human papiloma virus infections and related disorders, including cervical cancer. The composition of the invention acts enhancing genital immunity against infectious agents and re-epithelising damaged tissue.
    Type: Grant
    Filed: March 13, 2015
    Date of Patent: December 29, 2020
    Assignee: PROCARE HEALTH IBERIA, S.L.
    Inventors: Fernando Losa Dominguez, Santiago Palacios, Yann Gaslain
  • Patent number: 10844379
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine.
    Type: Grant
    Filed: December 26, 2018
    Date of Patent: November 24, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Thazha P. Prakash, Punit P. Seth, Eric E. Swayze
  • Patent number: 10821123
    Abstract: A method for treating a human subject having congestive heart failure is disclosed herein. An exemplary method includes orally administering a 10 g to 50 g dose of D-ribose daily to a subject having congestive heart failure, wherein the D-ribose is administered in a single dose after fasting, and the administration of D-ribose is continued over a period of time effective to improve cardiac and/or physical function of the subject.
    Type: Grant
    Filed: January 19, 2017
    Date of Patent: November 3, 2020
    Assignee: Bioenergy Life Science, Inc.
    Inventors: Jeffrey A. Thompson, Raj Khankari
  • Patent number: 10815264
    Abstract: The present application relates to novel nucleoside derivatives of formula (I) as claimed in claim 1, pharmaceutical compositions comprising the compounds, processes of preparation thereof, and methods of use thereof for treating cancer.
    Type: Grant
    Filed: May 25, 2016
    Date of Patent: October 27, 2020
    Assignee: Southern Research Institute
    Inventors: Cyril B. Dousson, David Dukhan, Jean-Laurent Paparin, Christophe C. Parsy
  • Patent number: 10780104
    Abstract: This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: September 22, 2020
    Inventors: Jin Q. Cheng, Said M. Sebti
  • Patent number: 10744148
    Abstract: This application relates to combination therapies including triciribine compounds and epidermal growth factor receptor inhibitor compounds, particularly erlotinib-like compounds and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: August 18, 2020
    Inventors: Jin Q. Cheng, Said M. Sebti
  • Patent number: 10744120
    Abstract: The present invention is directed to a combination comprising a glucocorticoid and a compound of formula I or a pharmaceutically acceptable salt thereof: to a pharmaceutical composition and to a kit both comprising said combination, to the combination, composition or kit for use in the treatment of cancer, and to a method of treatment of cancer in a patient in need thereof comprising administering to said patient an effective amount of said combination, composition or kit.
    Type: Grant
    Filed: May 26, 2015
    Date of Patent: August 18, 2020
    Assignee: PURDUE PHARMACEUTICAL PRODUCTS L.P.
    Inventors: Thomas Jorg Mehrling, Enrique Maria Ocio
  • Patent number: 10624918
    Abstract: An aqueous formulation for topical application to the skin comprising water, a water-miscible organic solvent, and benzoyl peroxide, wherein the concentration of the organic solvent is sufficient to provide a stable suspension of benzoyl peroxide in the aqueous formulation without the inclusion of a surfactant in the formulation, wherein the ratio of concentrations of water and organic solvent in the formulation is sufficient to maintain the benzoyl peroxide in saturated solubility in the formulation following application to the skin, and wherein the concentration of benzoyl peroxide in the formulation is less than 5.0% and at least 1.0% w/w. The formulation may further contain a chemical compound in addition to benzoyl peroxide that is effective in the treatment of acne. The aqueous formulations of the invention are useful in the treatment of acne and acne rosacea.
    Type: Grant
    Filed: October 26, 2018
    Date of Patent: April 21, 2020
    Assignee: Dow Pharmaceutical Sciences, Inc.
    Inventors: Yunik Chang, Gordon J. Dow, Radhakrishnan Pillai
  • Patent number: 10603334
    Abstract: Methods and compositions for preventing or treating peripheral neuropathy, cognitive deficits, inactivity, depression, chemotherapy and/or radiotherapy induced peripheral neuropathy and cognitive deficits, and improving cognitive performance, in a subject in need thereof are disclosed. The disclosed methods include the step of administering to the subject an effective amount of an agent that increases the level of NAD+ in the subject.
    Type: Grant
    Filed: April 28, 2016
    Date of Patent: March 31, 2020
    Assignee: NewSouth Innovation Pty. Limited
    Inventors: Lindsay Edward Wu, David A. Sinclair
  • Patent number: 10570169
    Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the gomeric compounds are conjugated to N-Acetylgalactosamine or to N-Acetylgalactosamine analogues.
    Type: Grant
    Filed: May 21, 2015
    Date of Patent: February 25, 2020
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Punit P. Seth, Thazha P. Prakash, Michael T. Migawa, Eric E. Swayze
  • Patent number: 10513706
    Abstract: A recombinantly expressed nucleotide triphosphate transporter efficiently imports the triphosphates of unnatural nucleotides into cells, and the endogenous cellular machinery incorporates those nucleotides into cellular nucleic acids. UBPs can therefore form within the cell's nucleic acids. Moreover, neither the presence of the unnatural triphosphates nor the replication of the UBP represents a significant growth burden. The UBP is not efficiently excised by nucleic acid repair pathways, and therefore can be retained as long as the unnatural triphosphates are available in the growth medium. Thus, the resulting cell is the first organism to stably propagate an expanded genetic alphabet.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: December 24, 2019
    Assignee: The Scripps Research Institute
    Inventors: Floyd E. Romesberg, Denis A. Malyshev
  • Patent number: 10487061
    Abstract: The disclosure describes methods of synthesis of phosphonate ester compounds. The methods according to the disclosure allow for large-scale preparation of phosphonate ester compounds having high purity and stability. Also disclosed are morphic forms of phosphonate ester compounds.
    Type: Grant
    Filed: September 19, 2018
    Date of Patent: November 26, 2019
    Assignee: Chimerix, Inc.
    Inventors: Roy Wendell Ware, Aaron Leigh Downey
  • Patent number: 10485813
    Abstract: The invention relates to novel compositions and methods of using maribavir which enhance its effectiveness in medical therapy, as well as to maribavir isomers and methods of use thereof for counteracting the potentially adverse effects of maribavir isomerization in vivo in the event it occurs.
    Type: Grant
    Filed: October 12, 2016
    Date of Patent: November 26, 2019
    Assignee: Shire ViroPharma Incorporated
    Inventor: John D. Peabody, III
  • Patent number: 10426769
    Abstract: The present invention is based on the fact that imiquimod, which is a substance that enhances Toll-like receptor 7 (TLR7) related to the innate immunity of a living body, is effective in the prevention and treatment of obesity or liver disease, and the present invention relates to a pharmaceutical composition for the prevention and treatment of obesity or liver disease, wherein the TLR7 agonist used for the immune system disease inhibits fatty acid synthetase (FAS), activates autophagosome or inhibits IGF-1.
    Type: Grant
    Filed: May 4, 2016
    Date of Patent: October 1, 2019
    Assignees: KNOTUS CO., LTD., KNOTUS LIFE SCIENCE INC.
    Inventors: Do Hyeong Kim, Sok Ho Kim, Jung Kee Kwon
  • Patent number: 10357516
    Abstract: The present invention provides pathogen-inactivated red blood cell compositions.
    Type: Grant
    Filed: June 20, 2017
    Date of Patent: July 23, 2019
    Assignee: Cerus Corporation
    Inventors: Naheed Mufti, Anna Erickson, Anne North
  • Patent number: 10344046
    Abstract: The present invention discloses compounds of formula (I): which exhibit antiviral properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of anti-HBV treatment. The invention also relates to methods of treating a HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: March 15, 2018
    Date of Patent: July 9, 2019
    Assignee: Spring Bank Pharmaceuticals, Inc.
    Inventors: Radhakrishnan P. Iyer, Seetharamaiyer Padmanabhan
  • Patent number: 10251903
    Abstract: The present invention is directed to a process for making Nucleoside Phosphoramidate Compounds of formula (I): which are useful for the treatment and prophylaxis of HCV infection. The present invention is also directed to compounds that are useful as synthetic intermediates for making the compounds of formula (I).
    Type: Grant
    Filed: October 20, 2015
    Date of Patent: April 9, 2019
    Assignees: Merck Sharp & Dohme Corp., Idenix Pharmaceuticals LLC
    Inventors: Bryon L. Simmons, Kevin R. Campos, Artis Klapars, Alistair J. Stewart, Benjamin A. Mayes, Peter E. Maligres, Alan Hyde, Steven Mark Silverman, Yong-Li Zhong, Adel M. Moussa, Kenneth Baker, Kara Van Valkenburg
  • Patent number: 10239912
    Abstract: Compounds that modulate the conversion of AMP to adenosine by 5?-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5?-nucleotidase, ecto is also provided.
    Type: Grant
    Filed: January 6, 2017
    Date of Patent: March 26, 2019
    Assignee: ARCUS BIOSCIENCES, INC.
    Inventors: Laurent Pierre Paul Debien, Juan Carlos Jaen, Jaroslaw Kalisiak, Kenneth V. Lawson, Manmohan Reddy Leleti, Erick Allen Lindsey, Dillon Harding Miles, Eric Newcomb, Jay Patrick Powers, Brandon Reid Rosen, Ehesan Ul Sharif
  • Patent number: 10238678
    Abstract: The present invention features a method for the treatment of Hepatitis C in a human in need thereof comprising administering a compound of Formulas (II) or (IIB) described herein or a pharmaceutically acceptable salt thereof in combination with one or more alternative Hepatitis C therapeutic agents.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: March 26, 2019
    Assignee: GlaxoSmithKline LLC
    Inventors: Jill Walker, Christian Voitenleitner
  • Patent number: 10179144
    Abstract: The present disclosure describes various formulations and compositions for improving one's vitality and health. The formulations may be particularly useful for treating or alleviating at least erectile dysfunction, increasing muscle mass, and encouraging saliva and tear production. In one example such a composition may include 1-methylfolate, methylcobalamin, n-acetylcysteine, pterostilbene, and nicotinamide riboside.
    Type: Grant
    Filed: January 10, 2018
    Date of Patent: January 15, 2019
    Inventor: Roger F. Duronio
  • Patent number: 10160750
    Abstract: The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: December 25, 2018
    Assignee: Bristol-Myers Squibb Company
    Inventors: Leon M. Smith, II, Donald J. P. Pinto, James R. Corte, William R. Ewing
  • Patent number: 10076534
    Abstract: The inventors have determined, contrary to the prior art and experience, how to successfully use triciribine to treat ovarian cancer by one or a combination of (i) administering triciribine only to patients which according to a diagnostic test described below, exhibit enhanced sensitivity to the drug; (ii) use of a described dosage level that minimizes the toxicity of the drug but yet still exhibits efficacy; or (iii) use of a described dosage regimen that minimizes the toxicity of the drug.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: September 18, 2018
    Assignee: University of South Florida
    Inventor: Jin Q. Cheng
  • Patent number: 10072262
    Abstract: The present invention relates to new triphosphate-modified oligonucleotides which may act as RIG-I ligands as well as a new method allowing the synthesis and purification in high yield and purity suitable for pharmaceutical applications.
    Type: Grant
    Filed: March 27, 2015
    Date of Patent: September 11, 2018
    Assignee: Rheinische Friedrich-Wilhelms-Universität Bonn
    Inventors: Marion Goldeck, Jasper Van Den Boorn, János Ludwig, Christine Schuberth-Wagner
  • Patent number: 10058507
    Abstract: Compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: August 28, 2018
    Assignee: CELATOR PHARMACEUTICALS, INC.
    Inventors: Paul Tardi, Troy Harasym, Murray Webb, Clifford Shew, Andrew Janoff, Lawrence Mayer, Marcel Bally
  • Patent number: 10047114
    Abstract: The present invention discloses compounds of formula (I): which exhibit antiviral properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of anti-HBV treatment. The invention also relates to methods of treating a HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    Type: Grant
    Filed: November 12, 2015
    Date of Patent: August 14, 2018
    Assignee: Spring Bank Pharmaceuticals, Inc.
    Inventors: Radhakrishnan P. Iyer, Seetharamaiyer Padmanabhan
  • Patent number: 9861651
    Abstract: The invention provides a method of preventing or treating hearing loss in a mammal in need thereof. The method involves administering to the mammal an agent that increases intracellular NAD+ in the mammal. The invention also provides a method of determining if a compound acts as a neuroprotective agent.
    Type: Grant
    Filed: July 15, 2013
    Date of Patent: January 9, 2018
    Assignee: CORNELL UNIVERSITY
    Inventors: Kevin Brown, Anthony Sauve, Samie Jaffrey
  • Patent number: 9849116
    Abstract: Pharmaceutical compositions of (R)-pramipexole and one or more secondary therapeutic agents such as, for example, dopamine agonists, dopaminergic agonists, COMT inhibitors, MOA inhibitors, excitatory amino acid antagonists, growth factors, neurotrophic factors, antioxidants, anti-inflammatory agents, immunomodulators, anti-glutamatergics, ion channel blockers, ?-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonists, heat shock protein inducers/protein disaggregators and downregulators, monoamine oxidase type B (MOAB) inhibitors, multi-target agents, kinase inhibitors, Bcl inducers, histone deacetylase (HDAC) mediators, glial modulators, mitochondrial energy promoting agents, myostatin inhibitors, caspase inhibitors and combinations thereof or those related to mitochondrial dysfunction or increased oxidative stress are disclosed.
    Type: Grant
    Filed: October 8, 2015
    Date of Patent: December 26, 2017
    Assignee: Knopp Biosciences LLC
    Inventors: Michael E. Bozik, Valentin Gribkoff, Thomas Petzinger, Jr.
  • Patent number: 9828408
    Abstract: The invention provides compounds of the formula: wherein B is a nucleobase selected from the groups (a) to (d): and the other variables are as defined in the claims, which are of use in the treatment or prophylaxis of hepatitis C virus infection, and related aspects.
    Type: Grant
    Filed: November 23, 2016
    Date of Patent: November 28, 2017
    Assignee: MEDIVIR AB
    Inventors: Genadiy Kalayanov, Staffan Torssell, Horst Wahling
  • Patent number: 9821173
    Abstract: An anti-cancer agent includes Au(I) purinyl, indolyl, or azaindolyl analogues encapsulated in sterically hindered phosphine ligands.
    Type: Grant
    Filed: February 10, 2014
    Date of Patent: November 21, 2017
    Assignee: Case Western Reserve University
    Inventor: Anthony J. Berdis